Literature DB >> 9436284

Stage T1c prostate cancer: defining the appropriate staging evaluation and the role for pelvic lymphadenectomy.

M C Beduschi1, R Beduschi, J E Oesterling.   

Abstract

A good staging system should be able to accurately reflect the natural history of a malignant disease, to express the extent of the disease at the time of diagnosis, and stratify patients in prognostically distinctive groups. The staging system for prostate cancer, as it is today, fails to fulfill these requirements. Approximately one third of the patients who undergo surgery for complete excision of prostate cancer in fact do not have a localize disease. The incidence of tumor at the inked margin may reach 30% for T1 stage and up to 60% for clinical T2b prostate cancer according to comparison with pathologic examination of resected specimen. Several concepts have been recently proposed as a means of improving the accuracy of the available staging system. In this paper, we review current aspects of clinical and pathological staging of prostate cancer, and the importance of these new concepts on the early stages of prostate cancer.

Entities:  

Mesh:

Year:  1997        PMID: 9436284     DOI: 10.1007/bf01300182

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  96 in total

1.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.

Authors:  T A Stamey; N Yang; A R Hay; J E McNeal; F S Freiha; E Redwine
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

2.  Relationship between perineural tumor invasion on needle biopsy and radical prostatectomy capsular penetration in clinical stage B adenocarcinoma of the prostate.

Authors:  S I Bastacky; P C Walsh; J I Epstein
Journal:  Am J Surg Pathol       Date:  1993-04       Impact factor: 6.394

3.  Survival rates of patients with prostatic cancer, tumor stage, and differentiation--preliminary report.

Authors:  J C Bailar; G T Mellinger; D F Gleason
Journal:  Cancer Chemother Rep       Date:  1966-03

4.  Enhanced reverse transcriptase-polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer.

Authors:  A E Katz; G M de Vries; M D Begg; A J Raffo; C Cama; K O'Toole; R Buttyan; M C Benson; C A Olsson
Journal:  Cancer       Date:  1995-04-01       Impact factor: 6.860

5.  Predictive value of contralateral biopsies in unilaterally palpable prostate cancer.

Authors:  G F Daniels; J E McNeal; T A Stamey
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

Review 6.  The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy.

Authors:  J S Wolf; M Cher; M Dall'era; J C Presti; H Hricak; P R Carroll
Journal:  J Urol       Date:  1995-03       Impact factor: 7.450

7.  Digital rectal examination, imaging, and systematic-sextant biopsy in identifying operable lymph node-negative prostatic carcinoma.

Authors:  P Hammerer; H Huland; A Sparenberg
Journal:  Eur Urol       Date:  1992       Impact factor: 20.096

8.  Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

Authors:  William J Catalona; Jerome P Richie; Frederick R Ahmann; M'Liss A Hudson; Peter T Scardino; Robert C Flanigan; Jean B DeKernion; Timothy L Ratliff; Louis R Kavoussi; Bruce L Dalkin; W Bedford Waters; Michael T MacFarlane; Paula C Southwick
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

9.  Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer.

Authors:  D L Bluestein; D G Bostwick; E J Bergstralh; J E Oesterling
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

10.  Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy.

Authors:  A W Partin; S Piantadosi; M G Sanda; J I Epstein; F F Marshall; J L Mohler; C B Brendler; P C Walsh; J W Simons
Journal:  Urology       Date:  1995-05       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.